Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 15:14:57 GMT -5
And I agree on the DTC.. disappointed.. No matter how much training/education is done, Only DTC can reach the far corners as they cant train/educate 100% of the targets and not 100% of the targets trained will actively prescribe Afrezza. some times the patient demands it too.. Given how different Afrezza works than RAAs don't you think it is worth it to spend some time getting docs to understand and buy into Afrezza so they are comfortable writing for it rather than shoving it down their throats and risk a big backlash? Q3 DTC also gives them time to redo label with data from Europe i.e. ultra rapid and reduced hypos, No?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 15, 2015 15:26:24 GMT -5
“Victorious warriors win first and then go to war, while defeated warriors go to war first and then seek to win”
― Sun Tzu, The Art of War
|
|
|
Post by jpg on Apr 15, 2015 15:50:43 GMT -5
What would be the point of starting DTC and have patients show up at doctors offices unaware, reticent and ill equipped?
Sorry to say this but the script count will suck for a while and we just have to get used to it. Will the 95 million short shares use this? Yes certainly but at the same time there is some pretty good money to be made off them while waiting. I think that is what we are seeing now. A staring game between 2 well funded groups who expect capitulation from the other side and the battle lines seem to be drawn at around 5$. The volume seems to indicate there is no active battle right now. When will this change? I really would be interested in the opinion of those with more market experience then me on this issue.
|
|
|
Post by zieg on Apr 15, 2015 15:54:52 GMT -5
He said that there were about 1500-2000 at the training in Vegas earlier in the year. Of those, I'm not sure how many will be Afrezza only. I do know that he is excited about the opportunity and will be paid incentives per script. This is the first time in his 10 year history w/SNY that there has been this opportunity to "cash in" w/a direct correlation of income generated per script written. They are still in the education phase and he's been doing presentations to hospital groups and doctors offices daily. He said that the feedback has been very positive, but we need to understand that the doctors, testing, and patient visit cycle takes time. The majority of patients do not know about Afrezza and that's because the doctors first need to be informed.
As a sales consultant for 19 years for a French company: Loreal (Redken, Loreal, Pureology, Matrix, Essie) , I feel like an idiot if my customers ask me for something before I've been trained on it . If my customers tell me they have clients asking for something they read about and I haven't shown it to them, it kills everyone's credibility and the salons I sell to don't look like the professionals on top of their game. I'm sure SNY is running the same philosophy.
|
|
|
Post by jpg on Apr 15, 2015 16:06:24 GMT -5
He said that there were about 1500-2000 at the training in Vegas earlier in the year. Of those, I'm not sure how many will be Afrezza only. I do know that he is excited about the opportunity and will be paid incentives per script. This is the first time in his 10 year history w/SNY that there has been this opportunity to "cash in" w/a direct correlation of income generated per script written. They are still in the education phase and he's been doing presentations to hospital groups and doctors offices daily. He said that the feedback has been very positive, but we need to understand that the doctors, testing, and patient visit cycle takes time. The majority of patients do not know about Afrezza and that's because the doctors first need to be informed. As a sales consultant for 19 years for a French company: Loreal (Redken, Loreal, Pureology, Matrix, Essie) , I feel like an idiot if my customers ask me for something before I've been trained on it . If my customers tell me they have clients asking for something they read about and I haven't shown it to them, it kills everyone's credibility and the salons I sell to don't look like the professionals on top of their game. I'm sure SNY is running the same philosophy. Thank you for this. As a physician I can say how hard it is to accept a different way of treating diabetics or any other disease. Change is hard for everyone. Getting people walking in off the street asking for a new medication physicians have barely heard of is not what we want.
|
|
|
Post by harryx1 on Apr 15, 2015 17:01:27 GMT -5
|
|
|
Post by kc on Apr 15, 2015 20:55:43 GMT -5
Good to see that Sanofi is working with nurses on training.
|
|
|
Post by gomnkd on Apr 18, 2015 8:18:50 GMT -5
I read the portion of "wide lens" book that covers the Exubera issue. My takeaways
1) the entire industry thought of inhaled insulin as next breakthrough and poured $. Some joined the party for competitive reasons. If you notice PK profile for all, you'll notice only MNKD got the physiologic profile. Rest look more like RAA. 2) everyone thought IH would expand the entire market. 3) book cites size of device, access to spirometer for endos, getting two endo appt as chief causes. We fixed the first one, but not the latter two. In fact, situation might be worse now for latter two.
I would suggest Sanofi offer free spirometers and training for endos. Forget the donuts and sandwiches.
The ONE thing in our favor is that mgmt understands the logistical issues and seems to take a measured, methodical approach. Like blind squirrels finding an occasional nut, the current pt are finding out about Afrezza.
The change in climate after debacle has royally screwed MNKD holders. If stock had traded higher, they could have issued at higher prices, reducing dilution. THIS IS ONE LOOOOOONG ROAD AHEAD. If you are patient, your grand kids will thank you.
|
|
|
Post by nemzter on Apr 18, 2015 8:37:25 GMT -5
I read the portion of "wide lens" book that covers the Exubera issue. My takeaways 1) the entire industry thought of inhaled insulin as next breakthrough and poured $. Some joined the party for competitive reasons. If you notice PK profile for all, you'll notice only MNKD got the physiologic profile. Rest look more like RAA. 2) everyone thought IH would expand the entire market. 3) book cites size of device, access to spirometer for endos, getting two endo appt as chief causes. We fixed the first one, but not the latter two. In fact, situation might be worse now for latter two. I would suggest Sanofi offer free spirometers and training for endos. Forget the donuts and sandwiches. The ONE thing in our favor is that mgmt understands the logistical issues and seems to take a measured, methodical approach. Like blind squirrels finding an occasional nut, the current pt are finding out about Afrezza. The change in climate after debacle has royally screwed MNKD holders. If stock had traded higher, they could have issued at higher prices, reducing dilution. THIS IS ONE LOOOOOONG ROAD AHEAD. If you are patient, your grand kids will thank you. Great point! Something someone should mention this at the Shareholders meeting
|
|
|
Post by kball on Apr 18, 2015 8:51:35 GMT -5
I read the portion of "wide lens" book that covers the Exubera issue. My takeaways 1) the entire industry thought of inhaled insulin as next breakthrough and poured $. Some joined the party for competitive reasons. If you notice PK profile for all, you'll notice only MNKD got the physiologic profile. Rest look more like RAA. 2) everyone thought IH would expand the entire market. 3) book cites size of device, access to spirometer for endos, getting two endo appt as chief causes. We fixed the first one, but not the latter two. In fact, situation might be worse now for latter two. I would suggest Sanofi offer free spirometers and training for endos. Forget the donuts and sandwiches. The ONE thing in our favor is that mgmt understands the logistical issues and seems to take a measured, methodical approach. Like blind squirrels finding an occasional nut, the current pt are finding out about Afrezza. The change in climate after debacle has royally screwed MNKD holders. If stock had traded higher, they could have issued at higher prices, reducing dilution. THIS IS ONE LOOOOOONG ROAD AHEAD. If you are patient, your grand kids will thank you. If this isn't part of at least a potential strategy for market penetration I have know idea why. Its like giving the market razors so you can charge them in perpetuity for blades and shaving cream. (or perhaps giving the market a "mirror", so you can charge them for razors, blades, and shaving cream...whichever one thinks is more clever i'm fine with) Good call GOMNKD
|
|
|
Post by tripoley on Apr 18, 2015 9:34:50 GMT -5
"I would suggest Sanofi offer free spirometers and training for endos. Forget the donuts and sandwiches."
Not a bad idea and they would only need to do this with a select few. I'm sure SNY could get a volume discount on spirometers for <$500 per device. Maybe set up 1,000 endos with well known prescribing habits for $500,000. That's like one round of exercised stock options for management.
|
|
|
Post by kball on Apr 21, 2015 9:25:20 GMT -5
Can we get a dr to chime in on the importance and sequence of Marketing to "them" (the medical community) vs marketing to consumers? I know pharma spends the majority to reach dr's etc. But i'm just curious as to how much and how soon these things tend to occur.
|
|